

Fig. 4. (A) Serum from an HCV patient was used to infect Huh-7.5 cells, PH5CH8 cells, and three HPV E6E7-immortalized clones (HuS-E/1-3) for 24 h. After washing three times in phosphate-buffered saline (PBS), cells were cultured in fresh medium. Cells were then harvested and lysed at the indicated time points. The quantity of HCV genome RNA per 500 ng total RNA was determined by real-time RT-PCR analysis. (B) HuS-E/2 and HuS-T/2 cells both expressed CD81. Expression of CD81 (upper panel) and GAPDH as an internal control (lower panel) in 293 cells, freshly isolated P.H., cultured P.H., and Huh-7.5, HuS-E/2, and HuS-T/2 cells was investigated by RT-PCR. (C) Anti-CD81 antibodies blocked HCV infectivity. HCV infection was performed as described in (A) with the addition of CD81-specific (black bar) or anti-tubulin antibodies (control, white bar). (D) IFN α inhibits HCV multiplication in HuS-E/2 cells infected with HCV-containing serum. HuS-E/2 cells were infected with HCV as described in (A). After washing three times with PBS, cells were cultured in fresh medium supplemented with (black bar) or without (white bar) 100 U/ml IFN α .

without or with 100 U/ml IFN α . The enhancement of the HCV-RNA genome titers on the fifth day (about 10-fold) was not observed in cells treated continuously with IFN α (Fig. 4D). This result suggests that IFN α inhibited HCV replication in infected HuS-E/2 cells.

3.7. The effect of blocking IRF-3 and IRF-7 signaling on HCV infectivity

Production of interferon-alpha (IFN α) and interferon-beta (IFN β) limits viral replication and spread, providing one of the most effective innate antiviral responses [25]. Signaling through IRF-3 and IRF-7 plays important roles in the stimulation of IFN- α/β production [25]. To determine which molecules (IRF-3 or IRF-7) play an important role in modulation of the innate immune response against HCV infection in these cells, we first detected intrinsic expression of double-stranded RNA-stimulated Toll-like receptor (TLR) 3, the downstream effector IRF-3, single-stranded RNA-stimulated TLR7, and 8, and the downstream effectors MyD88 and IRF-7 by RT-PCR. TLR3 exhibited very low expression in freshly isolated hepatocytes, Huh-7.5, HuS-E/2, and HuS-T/2 cells, while TLR7, TLR8, MyD88, and IRF-7 were easily detectable in both freshly isolated and immortalized cell lines (Fig. 5A).

The abilities of DNIRF-3 and DNIRF-7 to inhibit IFN β and IFN α production by HuS-E/2 cells infected with Sendai virus were confirmed using assays of IFN β or IFN α promoter-driven luciferase reporters. DNIRF-3 exhibited strong inhibition of IFN β production (Fig. 5B) and weaker inhibition of IFN α transcription (Fig. 5C), while DNIRF-7 strongly inhibited IFN α production (Fig. 5C) and only weakly inhibited IFN β production (Fig. 5B).

We then assessed the inhibition of HCV infectivity by DNIRF-3 and DNIRF-7. Transient transfection with DNIRF-3, DNIRF-7, or an empty vector was performed prior to HCV infection. Using Effectene reagent, the efficiency of plasmid transfection into HuS-E/2 cells was approximately 70% (data not shown). While there was no significant effect of DNIRF-3 on HCV infectivity, DNIRF-7 demonstrated a marked increase in HCV titers on days 3 and 5 after infection in comparison to control cells (Fig. 5D). To confirm that the enhancement of HCV replication by DNIRF-7 is not mediated by the impairment of IRF-3 signaling by heterodimeric interactions between IRF-3 and DNIRF-7, we performed siRNA inhibition of IRF-3 and IRF-7. The reduction of IRF-3 and IRF-7 expression by siRNA was obvious by RT-PCR (Fig. 5E). siRNA-mediated suppression of either IRF-3 or IRF-7 inhibited IFN β and IFN α production




Fig. 5. (A) We examined the expression of TLR3, TLR7, TLR8, MyD88, IRF-3, and IRF-7, as well as GAPDH as an internal control in freshly isolated primary hepatocytes and Huh-7.5, HuS-E/2, and HuS-T/2 cells was investigated by RT-PCR. (B and C) HuS-E/2 cells were cotransfected with pIFN β -luc (B) or pIFN α -luc (C) with an expression plasmid encoding DNIRF-3, DNIRF-7, or the appropriate empty vector (pcDNA3 and PLXSH, respectively). Twenty-four hours later, cells were infected (black bar) with Sendai virus or mock-infected (white bar), then analyzed for luciferase activity after 12 h. (D) IRF-7, but not IRF-3, suppression enhanced HCV infectivity of HuS-E/2 cells. HuS-E/2 cells were transiently transfected with empty pcDNA3, DNIRF-3, empty pLXSH, or DNIRF-7 plasmids. Twenty-four hours later, serum from a patient with HCV was used to infect transfected cells for 24 h. After washing, cells were cultured in fresh medium. The cells were then harvested and lysed at the indicated time points. The quantity of HCV genome RNA per 500 ng total RNA was determined by real-time RT-PCR analysis. (E) IRF-3 and IRF-7 levels were suppressed by specific siRNAs. HuS-E/2 cells were transfected with control psiRNA-hTLR2, psiRNA-hIRF-3, or psiRNA-hIRF-7, then selected with Zeocin at 250 μ g/ml. Two weeks later, cells were harvested and assessed for the expression of IRF-3 and IRF-7 by RT-PCR. (F and G) HuS-E/2 cells were transfected with control psiRNA-hTLR2, psiRNA-hIRF-3, or psiRNA-hIRF-7, followed by selection in Zeocin at 250 μ g/ml. Two weeks later, cells were cotransfected with pIFN β -luc (F) or pIFN α -luc (G). Twenty-four hours later, cells were infected (black bar) with Sendai virus or mock-infected (white bar), then analyzed for luciferase activity after 12 h. (H) Transfected cells were infected with serum from HCV patient; HCV infectivity was assessed as described above.

in HuS-E/2 cells infected with Sendai virus in patterns similar to the effects seen following DNIRF-3 and DNIRF-7 expression, respectively (Figs. 5F and G). Blockade of IRF-7 expression resulted in a significantly higher titer of HCV after infection, while IRF-3 down-regulation did not have any significant effect on HCV titers (Fig. 5H). The enhancement of IRF-7 silencing by siRNA improved the infectivity of HCV (data not shown). These results suggest that IRF-7 plays the major role in the innate immune response to HCV in HuS-E/2 cells.

3.8. Establishment of stable DNIRF-7 expressing clones derived from HuS-E/2 cells

Since DNIRF-7 enhanced HCV infectivity, we transduced the plasmid encoding DNIRF-7 and a hygromycin-B resistance gene, into HuS-E/2 cells. Following selection with hygromycin-B, we obtained the HuS-E7/DN22 and HuS-E7/DN24 clones. As detected by RT-PCR, both clones demonstrated similar expression levels

of albumin, apolipoprotein-A1, and HNF4 as the parental HuS-E/2 cells (Fig. 6A). The HuS-E7/DN24 clone exhibited stronger expression of DNIRF-7 than the HuS-E7/DN22 clone by immunoblotting (Fig. 6B). The induction of IFN α in HuS-E7/DN24 in response to infection with an RNA virus (Sendai virus) was low in comparison to the parental HuS-E/2 and HuS-E7/DN22 clones, as detected by IFN α -luciferase reporter assay (Fig. 6C). HuS-E7/DN24 also exhibited a higher HCV infectability in comparison to parental HuS-E/2 cells and the HuS-E7/DN22 clone (Fig. 6D).

3.9. Infection of HuS-E7/DN24 cells with different HCV genotypes

Huh7.5 and HuS-E7/DN24 cells were separately infected with serums derived from 3 different HCV-patients or by JFH-1 concentrated medium (HCV-2a). Two serums were infected by HCV-1b, while the third by HCV-2b. Inoculated virus titer was adjusted to be the same in all cases. Except for JFH-1, which efficiently




Fig. 6. (A) The pLXSH-HA-DNIRF-7 plasmid was transfected into HuS-E/2 cells, followed by selection in 100 μ g/ml Hygromycin B. Two clones, HuS-E7/DN22 (lane 2) and HuS-E7/DN24 (lane 3), were obtained. We investigated the expression of albumin, apo-A, HNF4, and GAPDH as an internal control in parental HuS-E/2, HuS-E7/DN22, and HuS-E7/DN24 hepatocytes cultured for two weeks by RT-PCR. (B) Expression of HA-tagged DNIRF-7 (upper panel) and tubulin (control, lower panel) was detected by immunoblotting analysis. HuS-E/2 cells transiently transfected with either empty pLXSH vector (lane 1) or pLXSH-HA-DNIRF-7 (lane 2) were used as negative and positive controls, respectively, after 48 h. (C) HuS-E/2, HuS-E7/DN24, and HuS-E7/DN22 cells were transfected with IFN α -luc. HuS-E/2 cells were also cotransfected with pLXSH. All of these cells were then infected (black bar) or with Sendai virus or mock-infected, then analyzed for luciferase activity after 12 h. (D) HuS-E7/DN24 cells exhibited high infectivity to HCV samples derived from patient serum. HuS-E/2 cells were transiently transfected with empty pLXSH. Twenty-four hours later, serum from a recurrently transplanted HCV patient was used to infect transfected cells and HuS-E7/DN22 and HuS-E7/DN24 cells for 24 h. After washing three times, cells were cultured in fresh medium. Cells were then harvested and lysed at the indicated time points.




Fig. 7. The infectability of Huh-7.5 and HuS-E7/DN24 cells to different HCV genotypes. Huh-7.5 (A) and HuS-E7/DN24 (B) cells were infected with same titer of JFH1 (HCV-2a), two different HCV-1b serums and one HCV-2b serum. After removing the infected medium, the cells were washed in PBS and recultured in fresh medium. Cells were harvested and lysed at the indicated time points. The quantity of HCV genome RNA per 500 ng RNA was detected by real-time RT-PCR analysis.

replicated in Huh7.5 cells (Fig. 7A), HuS-E7/DN24 cells showed a higher and reproducible infectability for the different HCV strains than Huh7.5 cells (Fig. 7B). Similar higher infectability of HuS-E7/DN24 cells was observed with HCV-4a genotype (unpublished data). These results suggest that the high infectability of Huh-7.5 with JFH-1 is specific among the combinations of HCV strains and cell lines; while HuS-E7/DN24 cells were generally permissive to HCV-infected serum independent of HCV strains.

4. Discussion

This study demonstrates that ectopic expression of the HPV18/E6E7 genes in combination with hTERT could efficiently immortalize mature human hepatocytes, generating a cell line with stable expression of hepatocyte markers and functions for more than 30 weeks in culture. HuS-E/2 cells continuously exhibited higher expression of both HGF and HGFR than HuS-T/2 cells. This result suggests that HPV18/E6E7-immortalized hepatocytes maintain responsiveness to paracrine signals capable of inducing cell differentiation to a greater extent than SV40 T-immortalized hepatocytes. This conclusion is further supported by the increased expression of HNF4 in HuS-E/2 cells in comparison to HuS-T/2 cells. HNF4 is a major hepatocyte transcription factor, required for hepatocyte differentiation and liver-specific gene expression [26]. HNF4 drives hepatocytes differentiation by acting upstream in a transcription factor cascade that included HNF1 α [27]. HuS-E/2 cells continued to express HNF1 α throughout prolonged culture, while HuS-T/2 cells lost expression completely. Maintenance of hepatocellular functions was demonstrated by continuous and high expression of albumin, apolipoprotein-A, human transferrin, and E-cadherin by HuS-E/2 in comparison to HuS-T/2 cells. These differences became more pronounced in the late passages. In a similar manner, HuS-E/2 cells continued to express all of the examined CYP genes, with the exception of CYP 3A4, while HuS-T/2 cells lost expression of CYP 3A4, 1B, and 2E1 completely and displayed markedly lower expression of CYP 1B1 than HuS-E/2 cells. Thus, human hepatocytes immortalized by HPV E6/E7 transfection are phenotypically similar to primary hepatocytes, even during extended cultures.

Recently, it was reported that the JFH-1 strain and derived chimeras could only infect and propagate efficiently in Huh7.5.1 and Huh7.5 cells, both of which are subclones of Huh7 cells [7–9]. This limitation, however, may be specific to the JFH-1 strain, which may not accurately reflect the course of other HCV strains' infection. Thus, usage of HCV particles isolated from patient serum could be more useful to study authentic HCV infection. Using sera from HCV patients as a source

of infective virus, HPV18/E6E7-immortalized cell lines exhibited higher reproducible susceptibility to HCV infection than HuS-T, PH5CH8, and Huh-7.5 cell lines.

IRF3 and IRF7 play an important role in the activation of interferon signaling [28]. We suppressed the functions of IRF-3 or IRF-7 to assess their role in HCV infectivity. In fact, we observed significant increase of HCV replication in HuS-E/2 cells bearing dominant-negative IRF7 that impaired IFN signaling. The suppression of IRF-3, however, did not have any significant effect on HCV infectivity or replication in this cell line. This may result from the blockade of IRF-3 activation by an HCV NS3/4A serine protease [29] through at least two independent pathways that inhibit the TLR3-dependent and RIG-I-dependent signaling pathways [29–33]. Although HCV was shown to inhibit basal expression levels of IRF-7 at both mRNA and protein levels and it was shown that NS5A suppresses IRF-7-induced IFN α promoter activation [34], Stimulation of TLR7 was shown to activate IRF-7 and induce suppression of HCV replicon levels in Huh-7 cells [35]. This suggests that the inhibition of IRF7 by HCV is not complete. Using IRF-7-deficient (IRF-7 $^{-/-}$) mice, Honda [36] demonstrated that the transcription factor IRF-7 is essential for the induction of IFN α/β genes. We established a clone stably expressing DNIRF-7 (HuS-7E/DN24), which demonstrated higher infectivity with different HCV strains than the parental HuS-E/2 clone.

In summary, we have established a human hepatocyte-derived cell line that maintains the characteristic features of primary hepatocytes by transduction with HPV18/E6E7. This cell line is highly infectable by HCV, which suggests that these cells may be useful to characterize the molecular mechanisms involved with HCV infection and to develop novel HCV treatment modalities.

Acknowledgements

We thank Dr. Akagi at Osaka Bioscience Institute for providing hTERT expressing vector, Dr. Sakai at the Institute for Virus Research, Kyoto University, for providing HPV18/E6E7 expressing plasmid, and Dr. Taniguchi of the University of Tokyo for providing IFN β , and IFN α promoters' reporter plasmids. This work was supported by Grants-in-Aid for cancer research and for the second-term comprehensive 10-year strategies for cancer control from the Ministry of Health, Labor and Welfare, by Grants-in-Aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology, by Grants-in-Aid for the research for the future program from the Japanese society for the Promotion of Science. Dr. Hussein H. Aly is a receiver of the Japanese *Gakushu Shoreihi* scholarship and was partly supported by Prof. *Yassin A. El Ghaffar memorial scholarship* for the Improvement of Liver research in Egypt.

References

- [1] Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. *Semin Liver Dis* 2000;20:1–16.
- [2] Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001;358:958–965.
- [3] Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncalves Jr FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002;347:975–982.
- [4] Hadziyannis SJ, Sette Jr H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 2004;140:346–355.
- [5] Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. *N Engl J Med* 2004;350:2265–2271.
- [6] Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. *Ann Intern Med* 2002;136:288–292.
- [7] Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. *Nat Med* 2005;11:791–796.
- [8] Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. *Proc Natl Acad Sci USA* 2005;102:9294–9299.
- [9] Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. *Science* 2005;309:623–626.
- [10] Dellgado JP, Parouchev A, Allain JE, Pennarun G, Gauthier LR, Dutrillaux AM, et al. Long-term controlled immortalization of a primate hepatic progenitor cell line after Simian virus 40 T-Antigen gene transfer. *Oncogene* 2005;24:541–551.
- [11] Mizuguchi T, Mitaka T, Katsuramaki T, Hirata K. Hepatocyte transplantation for total liver repopulation. *J Hepatobiliary Pancreat Surg* 2005;12:378–385.
- [12] Isom HC, Tevethia MJ, Kreider JW. Tumorigenicity of simian virus 40-transformed rat hepatocytes. *Cancer Res* 1981;41:2126–2134.
- [13] Ray FA, Waltman MJ, Lehman JM, Little JB, Nickoloff JA, Kraemer PM. Identification of SV40 T-antigen mutants that alter T-antigen-induced chromosome damage in human fibroblasts. *Cytometry* 1998;31:242–250.
- [14] Chen WH, Lai WF, Deng WP, Yang WK, Lo WC, Wu CC, et al. Tissue engineered cartilage using human articular chondrocytes immortalized by HPV-16 E6 and E7 genes. *J Biomed Mater Res A* 2006;76:512–520.
- [15] Dimri G, Band H, Band V. Mammary epithelial cell transformation: insights from cell culture and mouse models. *Breast Cancer Res* 2005;7:171–179.
- [16] Harms W, Rothamel T, Miller K, Harste G, Grassmann M, Heim A. Characterization of human myocardial fibroblasts immortalized by HPV16 E6–E7 genes. *Exp Cell Res* 2001;268:252–261.
- [17] Shiga T, Shirasawa H, Shimizu K, Dezawa M, Masuda Y, Simizu B. Normal human fibroblasts immortalized by introduction of human papillomavirus type 16 (HPV-16) E6–E7 genes. *Microbiol Immunol* 1997;41:313–319.
- [18] Akimov SS, Ramezani A, Hawley TS, Hawley RG. Bypass of senescence, immortalization, and transformation of human hematopoietic progenitor cells. *Stem Cells* 2005;23:1423–1433.
- [19] Hung SC, Yang DM, Chang CF, Lin RJ, Wang JS, Low-Tone Ho L, et al. Immortalization without neoplastic transformation of human mesenchymal stem cells by transduction with HPV16 E6E7 genes. *Int J Cancer* 2004;110:313–319.
- [20] Wang G, Johnson GA, Spencer TE, Bazer FW. Isolation, immortalization, and initial characterization of uterine cell lines: an in vitro model system for the porcine uterus. *In vitro Cell Dev Biol Anim* 2000;36:650–656.
- [21] Hino H, Tateno C, Sato H, Yamasaki C, Katayama S, Kohashi T, et al. A long-term culture of human hepatocytes which show a high growth potential and express their differentiated phenotypes. *Biochem Biophys Res Commun* 1999;256:184–191.
- [22] Wataishi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. *Hepatology* 2003;38:1282–1288.
- [23] Murata T, Ohshima T, Yamaji M, Hosaka M, Miyanari Y, Hijikata M, et al. Suppression of hepatitis C virus replicon by TGF-beta. *Virology* 2005;331:407–417.
- [24] Dasgupta A, Hughey R, Lancin P, Larue L, Moghe PV. E-cadherin synergistically induces hepatospecific phenotype and maturation of embryonic stem cells in conjunction with hepatotrophic factors. *Biotechnol Bioeng* 2005;92:257–266.
- [25] Civas A, Island ML, Genin P, Morin P, Navarro S. Regulation of virus-induced interferon-A genes. *Biochimie* 2002;84:643–654.
- [26] Ishiyama T, Kano J, Minami Y, Iijima T, Morishita Y, Noguchi M. Expression of HNFs and C/EBP alpha is correlated with immunocytochemical differentiation of cell lines derived from human hepatocellular carcinomas, hepatoblastomas and immortalized hepatocytes. *Cancer Sci* 2003;94:757–763.
- [27] Wege H, Le HT, Chui MS, Liu L, Wu J, Giri R, et al. Telomerase reconstitution immortalizes human fetal hepatocytes without disrupting their differentiation potential. *Gastroenterology* 2003;124:432–444.
- [28] Mamane Y, Heylbroeck C, Genin P, Algarte M, Servant MJ, LePage C, et al. Interferon regulatory factors: the next generation. *Gene* 1999;237:1–14.
- [29] Foy E, Li K, Wang C, Sumpter Jr R, Ikeda M, Lemon SM, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. *Science* 2003;300:1145–1148.
- [30] Sumpter Jr R, Loo YM, Foy E, Li K, Yoneyama M, Fujita T, et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. *J Virol* 2005;79:2689–2699.
- [31] Breiman A, Grandvaux N, Lin R, Ottone C, Akira S, Yoneyama M, et al. Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon. *J Virol* 2005;79:3969–3978.
- [32] Li K, Foy E, Ferreón JC, Nakamura M, Ferreón AC, Ikeda M, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. *Proc Natl Acad Sci USA* 2005;102:2992–2997.
- [33] Foy E, Li K, Sumpter Jr R, Loo YM, Johnson CL, Wang C, et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. *Proc Natl Acad Sci USA* 2005;102:2986–2991.
- [34] Zhang T, Lin RT, Li Y, Douglas SD, Maxcey C, Ho C, et al. Hepatitis C virus inhibits intracellular interferon alpha expression in human hepatic cell lines. *Hepatology* 2005;42:819–827.
- [35] Lee J, Wu CC, Lee KJ, Chuang TH, Katakura K, Liu YT, et al. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. *Proc Natl Acad Sci USA* 2006;103:1828–1833.
- [36] Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. *Nature* 2005;434:772–777.



Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice

Shin-ichiro Nakagawa ^{a,d}, Takuya Umehara ^a, Chiho Matsuda ^a,
Shusuke Kuge ^b, Masayuki Sudoh ^c, Michinori Kohara ^{a,*}

^a Department of Microbiology and Cell Biology, The Tokyo Metropolitan Institute of Medical Science,
3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8613, Japan

^b Laboratory of Molecular and Biochemical Toxicology, Graduate School of Pharmaceutical Sciences,
Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai, Miyagi 980-8578, Japan

^c Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan

^d Discovery Research Laboratories, Nippon Shinyaku Co., Ltd., 14 Nishinoshō-monguchi-cho, Kisshoin, Minami-ku, Kyoto 601-8550, Japan

Received 22 November 2006

Available online 22 December 2006

Abstract

Persistent infection with hepatitis C virus (HCV) is a major cause of liver diseases such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Here we report that inhibition of heat shock protein 90 (Hsp90) is highly effective in suppressing HCV genome replication. In HCV replicon cells, HCV replication was reduced by Hsp90 inhibitors and by knockdown of endogenous Hsp90 expression mediated by small-interfering RNA (siRNA). The suppression of HCV replication by an Hsp90 inhibitor was prevented by transfection with Hsp90 expression vector. We also tested the anti-HCV effect of Hsp90 inhibition in HCV-infected chimeric mice with humanized liver. Combined administration of an Hsp90 inhibitor and polyethylene glycol-conjugated interferon (PEG-IFN) was more effective in reducing HCV genome RNA levels in serum than was PEG-IFN monotherapy. These results suggest that inhibition of Hsp90 could provide a new therapeutic approach to HCV infection.

© 2006 Elsevier Inc. All rights reserved.

Keywords: HCV; Hsp90; Replication; Replicon; Chimeric mouse with humanized liver

Infection with hepatitis C virus (HCV), the major causative agent of non-A, non-B hepatitis [1–3], can lead to chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma [4]. An estimated 170 million people worldwide are currently infected with HCV [5]. Combination therapy comprising polyethylene glycol-conjugated interferon (PEG-IFN) and ribavirin represents the current standard treatment for chronic HCV infection, although it has demonstrated limited success and causes some serious side effects [6–8]. The development of safer and more effective drugs for the treatment of HCV infection is therefore an urgent necessity.

HCV, a member of the *Flaviviridae* family, has a single-stranded RNA genome of positive polarity. The genome encodes a large precursor polyprotein which is cleaved by host and viral proteases to generate at least 10 functional viral proteins: core, envelope1, envelope2, p7, nonstructural protein 2 (NS2), NS3, NS4A, NS4B, NS5A, and NS5B [9,10].

Lohmann et al. [11] have established an HCV replicon system in which HCV subgenomic RNA autonomously replicates in HuH-7, a human hepatoma cell line (HCV replicon cells). This HCV replicon system allows one to investigate HCV genome replication in cell culture.

In this study we performed random screening with natural-product libraries using HCV subgenomic replicon cells and found that inhibitors of heat shock protein 90 (Hsp90)

* Corresponding author. Fax: +81 3 3828 8945.

E-mail address: mkohara@rinshoken.or.jp (M. Kohara).

inhibited HCV replication. We found that Hsp90 was an important host-derived factor that regulates HCV replication in an HCV replicon system. Using HCV-infected chimeric mice with humanized liver, which have recently been developed as a practical small animal model of HCV infection [12–14], we also demonstrated inhibition of native HCV replication in human liver cells by Hsp90 inhibitors.

Materials and methods

HCV replicon cells. Two types of human hepatoma HuH-7 cells carrying an HCV subgenomic replicon, FLR 3-1 (genotype 1b, Con-1) [15] and R6FLR-N (genotype 1b, strain N) [16], were maintained in Dulbecco's modified Eagle's medium supplemented with GlutaMAX™ I (Invitrogen, Carlsbad, CA, USA) and 0.5 mg/ml of G418 at 37 °C in 5% CO₂. The replicons were constructed as shown in Fig. 1A.

Infection of chimeric mice with HCV. Chimeric mice harboring a functional human liver cell xenograft were purchased from PhenixBio (Hiroshima, Japan). The chimeric mice were generated by transplanting human primary hepatocytes into severe combined immunodeficient (SCID) mice carrying the urokinase plasminogen activator transgene controlled by an albumin promoter. The chimeric mice used in this study had been improved over the original mice described by Tateno et al. [14], and they had a higher human hepatocyte substitution rate. Six weeks after hepatocyte transplantation, we intravenously injected each mouse with an HCV-infected patient's serum containing 10⁶ copies of HCV genotype 1b (HCR6; Accession No. AY045702). The protocols for animal experiments were approved by the Ethics Committee of The Tokyo Metropolitan Institute of Medical Science. The animals received humane care according to the guidelines of the National Institutes of Health. The HCV-infected patient who provided the serum gave written informed consent before blood sampling.

Administration of 17-DMAG and/or PEG-IFN. Starting on day 0, HCV-infected chimeric mice with humanized liver received intravenous injections of 4 mg/kg of 17-DMAG and/or subcutaneous injections of 30 µg/kg PEG-IFNα-2a (Chugai, Tokyo, Japan) according to the schedule shown in Table 1.

Quantification of HCV RNA by real-time PCR. Total RNA was purified from 1 µl of serum from chimeric mice with humanized liver by the acid guanidinium-phenol-chloroform method, and HCV RNA was quantified by real-time PCR as described by Takeuchi et al. [17].

Results

Effect of Hsp90 inhibitors on HCV replication in HCV replicon cells

We have developed two modified HCV replicon cell lines, FLR 3-1 (genotype 1b, Con-1) [15] and R6FLR-N (genotype 1b, strain N) [16]. The HCV replicons are composed of the HCV 5'-untranslated region (UTR) containing an internal ribosomal entry site (IRES), the first 45 nucleotides of the core protein gene, fusion genes for luciferase and neomycin phosphotransferase, the encephalomyocarditis virus (EMCV) IRES, HCV NS3 through NS5B, and the HCV 3'-UTR (Fig. 1A). The construct allows quantification of replication levels by measuring luciferase activity. Taking advantage of this feature, we performed random screening of potential anti-HCV compounds using FLR 3-1 cells. Geldanamycin and radicicol, both of which are well-known Hsp90 inhibitors, were included among the hits. To assess the effects of Hsp90 inhibition on the intracellular replica-

tion of HCV in more detail, we treated the two different types of HCV replicon cells (FLR 3-1 and R6FLR-N) with each of four different Hsp90 inhibitors, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), geldanamycin, herbimycin A, and radicicol. All of the Hsp90 inhibitors suppressed replication of the HCV replicon in both cell types in a dose-dependent manner. The half-maximal inhibitory concentration (IC₅₀) for HCV replication in FLR 3-1 cells was 4.4 nM for 17-DMAG, 5.5 nM for geldanamycin, 50 nM for herbimycin A, and 133 nM for radicicol (Fig. 1B, upper panel). In R6FLR-N cells, the IC₅₀ was 8.1 nM for 17-DMAG, 7.8 nM for geldanamycin, 180 nM for herbimycin A, and 125 nM for radicicol (Fig. 1B, lower panel). We also assessed the levels of HCV NS3 protein, which plays a key role in HCV replication, by Western blotting and immunostaining. Hsp90 inhibitors brought about a dose-dependent decrease in the levels of this protein (Fig. 1C and D).

Effect of Hsp90 knockdown by siRNA on HCV replication in HCV replicon cells

To examine whether suppression of the replication of the HCV replicon by Hsp90 inhibitors resulted from functional inhibition of Hsp90, we used small-interfering RNA (siRNA) to perform knockdown of Hsp90. In mammalian cells there are two Hsp90 isoforms, Hsp90α and Hsp90β, which are encoded by separate genes, so we transfected siRNA targeting Hsp90α, Hsp90β, or both Hsp90α and Hsp90β into FLR 3-1 cells. As a positive control, we used siE-R7 [16], an siRNA that is sequence specific for HCV IRES. As a negative control we used sip53m [16], an siRNA that is sequence specific for p53 mRNA except for two nucleotides. Replication of the HCV replicon was suppressed by siRNA against either Hsp90α or Hsp90β in a dose-dependent manner with no effect on cell viability (Fig. 2A and B). Double knockdown of both Hsp90α and Hsp90β suppressed replication of the HCV replicon more effectively than knockdown of either Hsp90α or Hsp90β alone. HCV replication was reduced to 50–60% of control levels when cells were treated with 70 nM siRNA targeting either Hsp90α or Hsp90β, but it fell to 30% of control when cells were treated with 35 nM siRNA against Hsp90α combined with 35 nM siRNA against Hsp90β (Fig. 2A). To confirm the functionality of the siRNAs, cells were treated with 100 nM siRNA and the expression of Hsp90 protein was assessed by Western blotting. siRNA against Hsp90α or Hsp90β specifically inhibited the expression of the corresponding Hsp90 protein (Fig. 2C). It was also observed that the expression of NS3 protein was downregulated in cells transfected with siRNA targeting either Hsp90α or Hsp90β (Fig. 2C). Moreover, when cells were cotransfected with siRNA against Hsp90α and siRNA against Hsp90β (each at a concentration of 50 nM), the expression of NS3 protein was more effectively downregulated than when cells were transfected with 100 nM of siRNA targeting either Hsp90α or Hsp90β alone (Fig. 2C).




Fig. 1. Effect of Hsp90 inhibitors on HCV replication and cell viability in HCV replicon cells. (A) Schematic representation of the HCV subgenomic replicons used in this study. Δ C, first 45 nucleotides of HCV core protein gene; neo-R, neomycin phosphotransferase gene. (B) Inhibition of replication of the HCV replicon by the Hsp90 inhibitors 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), geldanamycin (GA), herbimycin A (HMA), and radicicol (RAD) in FLR 3-1 replicon cells (upper panels) and R6FLR-N replicon cells (lower panels). Interferon- α (IFN- α) was used as a positive control. Seventy-two hours after treatment, HCV replication was determined by luciferase assay and cell viability by WST-8 assay. The data represent the mean of four values and the bars indicate the standard deviation. (C) FLR 3-1 cells were treated with IFN- α or Hsp90 inhibitors for 72 h. Saline was added to control cells. The levels of NS3 protein or β -actin were assessed by Western blotting. (D) FLR 3-1 cells were immunostained with anti-NS3 antibody (green) and diamidino-2-phenylindole (red). Cells were treated with saline (control) or with 10³ U/ml IFN- α , 5 nM 17-DMAG, 40 nM 17-DMAG, 5 nM GA, 40 nM GA, 50 nM HMA or 300 nM HMA as indicated.

Table 1
 Schedule of blood sampling and drug administration for chimeric mice infected with HCV

Day	-1	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14
Collection of blood	B					B										B
17-DMAG		D	D	D	D	D	D	D	D	D	D	D	D	D	D	
PEG-IFN		I			I				I			I				
17-DMAG + PEG-IFN		D/I	D	D	D/I	D	D	D	D/I	D	D	D/I	D	D	D	

B indicates sampling of blood; D, intravenous injection of 17-DMAG (4 mg/kg); I, subcutaneous injection of PEG-IFN (30 μ g/kg).




Fig. 2. Effect of knockdown or overexpression of Hsp90 on replication of the HCV replicon. (A,B) FLR 3-1 replicon cells were transfected with HCV-directed siRNA (siE-R7), negative-control siRNA (sip53m) or Hsp90-directed siRNA. Seventy-two hours after siRNA transfection, HCV replicon levels were determined by luciferase assay (A) and cell viability was determined by WST-8 assay (B). Saline was added to control cells. The data represent the mean of four values and the bars indicate the standard deviation. (C) Seventy-two hours after siRNA transfection, NS3, Hsp90 α , and Hsp90 β protein were quantified by Western blotting. (D) FLR 3-1 replicon cells were transfected with an expression vector encoding His-tagged Hsp90 α , Hsp90 β , or both Hsp90 α and Hsp90 β , or control empty vector and treated with 17-DMAG for 6 h. Forty-eight hours after treatment with 17-DMAG, HCV replicon levels were determined by luciferase assay. The data represent mean of four values and the bars indicate the standard deviation. The asterisks indicate significant differences between the Hsp90 expression vector and control vector groups at the corresponding concentration (* $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; Student's t -test). (E) Seventy-two hours after transfection with expression vector encoding His-tagged Hsp90, His-tag, Hsp90 α , and Hsp90 β protein were quantified by Western blotting.

Effect of complementation with Hsp90

We tested whether the reduction in HCV replicon replication caused by Hsp90 inhibitors could be prevented by transfection with an expression vector encoding Hsp90. FLR 3-1 cells were transfected with an expression vector encoding histidine (His)-tagged Hsp90 α , Hsp90 β , or both Hsp90 α and Hsp90 β , or an control empty vector (Fig. 2E), and pulse-stimulated with 17-DMAG for 6 h. As expected, replication of the HCV replicon in cells transfected with control vector was suppressed by 17-DMAG in a dose-dependent manner. In contrast, replication of the HCV replicon in cells transfected with an expression vector encoding Hsp90 α , Hsp90 β , or both Hsp90 α and Hsp90 β was significantly higher than in cells transfected with control empty vector, when cells were treated with 17-DMAG (Fig. 2D).

Anti-HCV effects of 17-DMAG and PEG-IFN in HCV-infected chimeric mice with humanized liver

The anti-HCV effect of Hsp90 inhibitors was investigated in chimeric mice with humanized liver injected with an HCV-infected patient's serum. Four weeks after infection,

HCV RNA levels had reached 2.3×10^6 – 1.4×10^7 copies/ml. We then administered 17-DMAG intravenously and/or PEG-IFN subcutaneously over a period of 14 days according to the schedule shown in Table 1. Blood samples were collected before, during, and after this period (Table 1). In the group treated with 30 $\mu\text{g}/\text{kg}$ of PEG-IFN, a dose 10-fold larger than that used in clinical treatment, HCV genome RNA levels had decreased in the serum 8.8-fold by day 4 and 11-fold by day 14 (Fig. 3A). Combined treatment with 4 mg/kg of 17-DMAG and 30 $\mu\text{g}/\text{kg}$ of PEG-IFN reduced HCV genome RNA levels significantly more than did PEG-IFN monotherapy. HCV genome RNA levels in the coadministration group had decreased 25-fold by day 4 and 45-fold by day 14 (Fig. 3A). In the group treated with 4 mg/kg of 17-DMAG, no reduction in HCV genome RNA levels was observed at this dose. We monitored the concentration of human albumin over the same period and observed no suppression of this protein during or after administration of 17-DMAG (Fig. 3B).

Discussion

In an effort to develop safer and more effective drug treatments, new antiviral agents, including inhibitors of




Fig. 3. Anti-HCV effect of 17-DMAG in HCV-infected chimeric mice. (A) HCV genome RNA levels in the serum of chimeric mice were determined by real-time PCR. (B) Human albumin concentrations in the sera of chimeric mice. The numbers 1–9 represent individual mice. Numbers 1, 2, and 3 were in the group treated with 4 mg/kg 17-DMAG, numbers 4, 5, and 6 were in the group treated with 30 μ g/kg polyethylene glycol-conjugated interferon (PEG-IFN), and numbers 7, 8, and 9 were in the group treated with 4 mg/kg 17-DMAG and 30 μ g/kg PEG-IFN. Asterisks indicate significant differences at the $P < 0.1$ level between the coadministration and PEG-IFN monotherapy groups on the same date.

the HCV NS3/4A serine protease and the HCV NS5B RNA-dependent RNA polymerase, are currently under clinical investigation [18]. However, it is likely that viral resistance will develop against antiviral agents that directly target viral enzymes, because of the error-prone nature of the virus reverse transcriptase and RNA-dependent RNA polymerase [19,20]. Therefore, we believe that anti-HCV therapies that target host-derived factors may be preferable to those that target a viral protein.

Recently, several host-derived factors that regulate replication of the HCV replicon or genome have been identified. Inhibitors of serine palmitoyltransferase have been found to suppress HCV replication in cultured cells and chimeric mice infected with HCV [15,21]. They act by preventing *de novo* synthesis of sphingolipids, major components of the lipid raft where HCV NS proteins associate. In other studies the immunosuppressant cyclosporin A has been shown to inhibit replication of the HCV genome [22,23], and cyclophilin B has been identified as the host-derived target of cyclosporin A [24,25].

In the present study, we tested the effects of Hsp90 inhibitors on HCV replication in cells carrying an HCV subgenomic replicon. All of the Hsp90 inhibitors we tested had potent anti-HCV activity. Using NS2/3 translated in a rabbit reticulocyte lysate and expressed in Jurkat cells, Waxman et al. [26] demonstrated a role for Hsp90 in pro-

moting the cleavage of HCV NS2/3 protein. Because the replicon cells used in our study genetically lacked NS2, our results suggest that Hsp90 may directly or indirectly interact with any of the proteins NS3 through NS5B to regulate replication of the HCV replicon. Recently, Okamoto et al. [27] have reported that FKBP8, an Hsp90 partner protein, directly interacts with NSSA and regulates HCV RNA replication.

We also performed siRNA knockdown of Hsp90 and found suppression of HCV replication, consistent with the results of our experiment with Hsp90 inhibitors. Moreover, the HCV replication suppressed by Hsp90 inhibitors was rescued by the expression of Hsp90. These results indicate that Hsp90 is critical for efficient replication of the HCV replicon and that both Hsp90 isoforms (Hsp90 α and Hsp90 β) participate in replication.

Although the HCV replicon system is useful for screening compounds with potential anti-HCV activity, the inhibitory effects on replication are not always consistent with those found for HCV genome RNA in HCV-infected human liver. To bridge the gap between the replicon system and native HCV replication in the human liver, we tested the anti-HCV effect of Hsp90 inhibitors in HCV-infected chimeric mice with humanized liver. Of the Hsp90 inhibitors we tested, we chose to administer 17-DMAG to the mice because it is highly specific and therefore less toxic, and also because it

is currently under clinical investigation for the treatment of cancer [28,29]. We found that 17-DMAG exerted an apparently synergistic anti-HCV effect when used in combination with PEG-IFN to treat HCV-infected chimeric mice with humanized liver. Furthermore, 17-DMAG did not alter the levels of human albumin, indicating that it did not cause appreciable damage to the human hepatocytes. These results suggest that 17-DMAG may be a promising agent for the treatment of HCV infection.

In conclusion, our results demonstrate that Hsp90 supports HCV RNA replication both in an HCV replicon system and in a humanized liver mouse model infected with HCV. In addition, our results suggest that inhibition of Hsp90 may provide a feasible therapeutic strategy for the treatment of HCV infection. The precise molecular mechanism by which Hsp90 participates in the replication of HCV RNA remains to be elucidated and is under investigation.

Acknowledgments

We thank Isao Maruyama and Hiroshi Yokomichi of PhenixBio Co., Ltd., for the maintenance of and technical assistance with the chimeric mice, and Dr. Gerald E. Smyth for helpful comments on the preparation of this manuscript. This study was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan; the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation of Japan; the Ministry of Health, Labor and Welfare of Japan.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.bbrc.2006.12.117.

References

- [1] H.J. Alter, R.H. Purcell, J.W. Shih, J.C. Melpolder, M. Houghton, Q.L. Choo, G. Kuo, Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis, *N. Engl. J. Med.* 321 (1989) 1494–1500.
- [2] Q.L. Choo, G. Kuo, A.J. Weiner, L.R. Overby, D.W. Bradley, M. Houghton, Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome, *Science* 244 (1989) 359–362.
- [3] K. Kiyosawa, T. Sodeyama, E. Tanaka, Y. Gibo, K. Yoshizawa, Y. Nakano, S. Furuta, Y. Akahane, K. Nishioka, R.H. Purcell, et al., Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus, *Hepatology* 12 (1990) 671–675.
- [4] I. Saito, T. Miyamura, A. Ohbayashi, H. Harada, T. Katayama, S. Kikuchi, Y. Watanabe, S. Koi, M. Onji, Y. Ohta, et al., Hepatitis C virus infection is associated with the development of hepatocellular carcinoma, *Proc. Natl. Acad. Sci. USA* 87 (1990) 6547–6549.
- [5] WHO, Hepatitis C—global prevalence (update), *Wkly. Epidemiol. Rec.* 75 (2000) 18–19.
- [6] J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, V.K. Rustgi, Z.D. Goodman, M.H. Ling, S. Cort, J.K. Albrecht, Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group, *N. Engl. J. Med.* 339 (1998) 1485–1492.
- [7] P. Glue, R. Rouzier-Panis, C. Raffanel, R. Sabo, S.K. Gupta, M. Salfi, S. Jacobs, R.P. Clement, A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group, *Hepatology* 32 (2000) 647–653.
- [8] K.R. Reddy, T.L. Wright, P.J. Pockros, M. Shiffman, G. Everson, R. Reindollar, M.W. Fried, P.P. Purdum 3rd, D. Jensen, C. Smith, et al., Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C, *Hepatology* 33 (2001) 433–438.
- [9] A. Grakoui, C. Wychowski, C. Lin, S.M. Feinstone, C.M. Rice, Expression and identification of hepatitis C virus polyprotein cleavage products, *J. Virol.* 67 (1993) 1385–1395.
- [10] M. Hijikata, H. Mizushima, T. Akagi, S. Mori, N. Kakiuchi, N. Kato, T. Tanaka, K. Kimura, K. Shimotohno, Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus, *J. Virol.* 67 (1993) 4665–4675.
- [11] V. Lohmann, F. Korner, J. Koch, U. Herian, L. Theilmann, R. Bartenschlager, Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line, *Science* 285 (1999) 110–113.
- [12] M. Dandri, M.R. Burda, E. Torok, J.M. Pollok, A. Iwanska, G. Sommer, X. Rogiers, C.E. Rogler, S. Gupta, H. Will, et al., Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus, *Hepatology* 33 (2001) 981–988.
- [13] D.F. Mercer, D.E. Schiller, J.F. Elliott, D.N. Douglas, C. Hao, A. Rinfret, W.R. Addison, K.P. Fischer, T.A. Churchill, J.R. Lakey, et al., Hepatitis C virus replication in mice with chimeric human livers, *Nat. Med.* 7 (2001) 927–933.
- [14] C. Tateno, Y. Yoshizane, N. Saito, M. Kataoka, R. Utoh, C. Yamasaki, A. Tachibana, Y. Soeno, K. Asahina, H. Hino, et al., Near completely humanized liver in mice shows human-type metabolic responses to drugs, *Am. J. Pathol.* 165 (2004) 901–912.
- [15] H. Sakamoto, K. Okamoto, M. Aoki, H. Kato, A. Katsume, A. Ohta, T. Tsukuda, N. Shimma, Y. Aoki, M. Arisawa, et al., Host sphingolipid biosynthesis as a target for hepatitis C virus therapy, *Nat. Chem. Biol.* 1 (2005) 333–337.
- [16] T. Watanabe, M. Sudoh, M. Miyagishi, H. Akashi, M. Arai, K. Inoue, K. Taira, M. Yoshida, M. Kohara, Intracellular-diced dsRNA has enhanced efficacy for silencing HCV RNA and overcomes variation in the viral genotype, *Gene Ther.* 13 (2006) 883–892.
- [17] T. Takeuchi, A. Katsume, T. Tanaka, A. Abe, K. Inoue, K. Tsukiyama-Kohara, R. Kawaguchi, S. Tanaka, M. Kohara, Real-time detection system for quantification of hepatitis C virus genome, *Gastroenterology* 116 (1999) 636–642.
- [18] Z.J. Ni, A.S. Wagman, Progress and development of small molecule HCV antivirals, *Curr. Opin. Drug Discov. Devel.* 7 (2004) 446–459.
- [19] C. Lin, C.A. Gates, B.G. Rao, D.L. Brennan, J.R. Fulghum, Y.P. Luong, J.D. Frantz, K. Lin, S. Ma, Y.Y. Wei, et al., In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061, *J. Biol. Chem.* 280 (2005) 36784–36791.
- [20] L. Tomei, S. Altamura, G. Paonessa, R. De Francesco, G. Migliaccio, HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase, *Antivir. Chem. Chemother.* 16 (2005) 225–245.
- [21] T. Umehara, M. Sudoh, F. Yasui, C. Matsuda, Y. Hayashi, K. Chayama, M. Kohara, Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse model, *Biochem. Biophys. Res. Commun.* 346 (2006) 67–73.
- [22] M. Nakagawa, N. Sakamoto, N. Enomoto, Y. Tanabe, N. Kanazawa, T. Koyama, M. Kurosaki, S. Maekawa, T. Yamashiro, C.H. Chen, et al., Specific inhibition of hepatitis C virus replication by cyclosporin A, *Biochem. Biophys. Res. Commun.* 313 (2004) 42–47.
- [23] K. Watashi, M. Hijikata, M. Hosaka, M. Yamaji, K. Shimotohno, Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes, *Hepatology* 38 (2003) 1282–1288.

- [24] M. Nakagawa, N. Sakamoto, Y. Tanabe, T. Koyama, Y. Itsui, Y. Takeda, C.H. Chen, S. Kakinuma, S. Oooka, S. Maekawa, et al., Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins, *Gastroenterology* 129 (2005) 1031–1041.
- [25] K. Watashi, N. Ishii, M. Hijikata, D. Inoue, T. Murata, Y. Miyanari, K. Shimotohno, Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase, *Mol. Cell* 19 (2005) 111–122.
- [26] L. Waxman, M. Whitney, B.A. Pollok, L.C. Kuo, P.L. Darke, Host cell factor requirement for hepatitis C virus enzyme maturation, *Proc. Natl. Acad. Sci. USA* 98 (2001) 13931–13935.
- [27] T. Okamoto, Y. Nishimura, T. Ichimura, K. Suzuki, T. Miyamura, T. Suzuki, K. Moriishi, Y. Matsuura, Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90, *EMBO J.* 25 (2006) 5015–5025.
- [28] S. Pacey, U. Banerji, I. Judson, P. Workman, Hsp90 inhibitors in the clinic, *Handb. Exp. Pharmacol.* (2006) 331–358.
- [29] Z.Q. Tian, Y. Liu, D. Zhang, Z. Wang, S.D. Dong, C.W. Carreras, Y. Zhou, G. Rastelli, D.V. Santi, D.C. Myles, Synthesis and biological activities of novel 17-aminogeldanamycin derivatives, *Bioorg. Med. Chem.* 12 (2004) 5317–5329.

Evaluation of a Cyclophilin Inhibitor in Hepatitis C Virus-Infected Chimeric Mice *In Vivo*

Kazuaki Inoue,^{1,2*} Takuya Umehara,^{1*} Urs T. Ruegg,³ Fumihiko Yasui,¹ Tsunamasa Watanabe,^{1,2} Hiroshi Yasuda,² Jean-Maurice Dumont,⁴ Pietro Scalfaro,⁴ Makoto Yoshida,² and Michinori Kohara¹

Cyclosporin A (CsA) inhibits replication of the HCV subgenomic replicon, and this effect is believed to not be mediated by its immunosuppressive action. We found that DEBIO-025, a novel non-immunosuppressive cyclophilin inhibitor derived from CsA, inhibited HCV replication *in vitro* more potently than CsA. We also examined the inhibitory effect of DEBIO-025 on naive HCV genotypes 1a or 1b *in vivo* using chimeric mice with human hepatocytes. These mice were treated for 14 days with DEBIO-025, pegylated-interferon α -2a (Peg-IFN), a combination of either drugs, or CsA in combination with Peg-IFN. In mice treated with Peg-IFN, serum HCV RNA levels decreased approximately 10-fold whereas DEBIO-025 treatment alone did not induce any significant change. In mice treated with both DEBIO-025 and Peg-IFN, HCV RNA levels decreased more than 100-fold. All mice treated with Peg-IFN combined with CsA died within 4 days. The combination treatment of DEBIO-025 and Peg-IFN reduced HCV RNA levels and core protein expression in liver, indicating that the HCV RNA levels reduction in serum was attributable to intrahepatic inhibition of HCV replication. **Conclusion:** We demonstrated that DEBIO-025 was better tolerated than CsA, and that its anti-HCV effect appeared to be synergistic in combination with Peg-IFN *in vivo*. (HEPATOLOGY 2007;45:921-928.)

Hepatitis C virus is a small enveloped RNA virus that belongs to the *Flaviviridae* family.¹ A hallmark of HCV infection is its high propensity to establish a persistent infection that evades the host immune response, leading to chronic liver disease, chronic hepatitis, cirrhosis, and hepatocellular carcinoma.^{2,3} Although approximately 170 million individuals are in-

fectured with HCV worldwide, drugs that are specifically active against hepatitis C are not yet available.

Currently, the main therapy for chronic hepatitis C is a combination of pegylated interferon alpha (Peg-IFN) and ribavirin. In the intention-to-treat analysis, this combination therapy led to a sustained virological response in approximately 55%^{4,5} of patients infected with any HCV genotype and in 42%⁴ to 46%⁵ of patients with genotype 1. The results of clinical trials were based on selected patients. The proportion of elderly patients was low, and patients with HBV or HIV coinfection, renal disease, post-transplantation status, or hematological disorders were excluded.⁴⁻⁸ Because approximately 50% of patients show a poor response to combined treatment with Peg-IFN and ribavirin, effective therapies are urgently needed.

We previously reported that combination therapy of interferon (IFN) α -2b and cyclosporin A (CsA) for 24 weeks produced a sustained virological response in 42% of patients with both HCV genotype 1b and high viral levels.⁹ High blood levels of CsA correlate with virological response during treatment for HCV, but occasionally can cause adverse events related to immunosuppression.¹⁰ CsA also suppresses HCV replication *in vitro*, by inhibiting the interaction between HCV nonstructural protein 5B and cyclophilin.¹¹

Abbreviations: CsA, cyclosporin A; Peg-IFN, pegylated-interferon α -2a.

From the ¹Department of Microbiology and Cell Biology, The Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan; the ²Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan; the ³Laboratory of Pharmacology, Geneva-Lausanne School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Switzerland; and ⁴Debiopharm SA Forum "après-demain" Chemin Messidor, Lausanne, Switzerland.

Received May 16, 2006; accepted November 27, 2006.

*These authors contributed equally to this work.

Supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan, the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation of Japan, the Ministry of Health, Labor and Welfare of Japan and the Medical Foundation of the Showa University Alumni Association.

Address reprint requests to: Kazuaki Inoue, M.D., Ph.D., Department of Microbiology and Cell Biology, The Tokyo Metropolitan Institute of Medical Science, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8613, Japan. E-mail: kinoue@rinshoken.or.jp; fax: (81) 3-3828-8945.

Copyright © 2007 by the American Association for the Study of Liver Diseases.

Published online in Wiley InterScience (www.interscience.wiley.com).

DOI 10.1002/hep.21587

Potential conflict of interest: Dr. Ruegg received grants from Debiopharm.




Fig. 1. (A) Structure of DEBIO-25, which was derived from CsA by substitution of amino acids at positions 3 and 4. (B) Scheme for IL-2 reporter gene assay. Nuclear factor of activated T cells (NF-AT), phorbol-12-myristate-13-acetate (PMA), phytohemagglutinin (PHA), 4-methyl umbelliferyl- β -D-galactoside (MUG).

CsA is an immunosuppressive agent widely used to improve graft survival after organ transplantation.¹² It was isolated as a metabolite from *Beauveria nivea* and consists of a cyclic polypeptide of 11 amino acids.¹³ DEBIO-025 is a synthetic compound showing a more potent cyclophilin inhibitory activity as compared with CsA¹⁴ and differing from CsA by the substitution of 2 amino acids (Fig. 1A; see Materials and Methods).¹⁵ DEBIO-025 lacks immunosuppressive effects, although it still has remarkable inhibitory effects on HCV replication *in vitro*.¹⁶

We report the *in vivo* effectiveness and tolerability of DEBIO-025 administered in combination with Peg-IFN in chimeric mice with human hepatocytes that were infected with HCV genotypes 1a or 1b.

Materials and Methods

Compounds. DEBIO-025 is a synthetic compound derived from CsA. Sarcosine (*N*-methyl-D-glycine) at position 3 and *N*-methyl-D-leucine at position 4 are substituted for *N*-methyl-D-alanine and *N*-ethyl-D-valine, respectively (Fig. 1A).¹⁶ DEBIO-025 was obtained from Döbiopharm (Lausanne, Switzerland). CsA was purchased from Fluka Chemie (Buchs, Switzerland), and Peg-IFN was purchased from Chugai Pharmaceutical Co. (Tokyo, Japan).

Anti-HCV Assay in HuH-7 Cells Harboring Subgenomic Replicons. We used 2 HCV subgenomic replicon cell lines, FLR3-1¹⁷ and R6FLR-N,¹⁸ which were constructed as shown in Fig. 2A. They were seeded at a density of 5×10^3 per well in 96-well tissue culture plates, in complete Dulbecco's modified Eagle's medium GlutaMax I (DMEM-GlutaMaxI; Invitrogen, Carlsbad, CA) and containing 5% fetal bovine serum (Invitrogen).^{17,18} The genome of the 2 replicons was genotype 1b. After incubation for 24 hours at 37°C (5% CO₂), the medium

was removed, and serial dilutions of DEBIO-025 or CsA in growth medium were added. After 72 hours, luciferase activity was determined using the Bright-Glo luciferase assay kit (Promega Madison, WI). The luciferase signal was measured in triplicate using an LB940 luminometer (Berthold, Freiburg, Germany), and the results were expressed as the average percentage of control. IC₅₀ values of DEBIO-025 and CsA were calculated by nonlinear curve fitting following the equation: $Y = 100 - (Y_{\text{Bottom}} \times X / (IC_{50} + X))$, where Y represents percentage inhibition and X represents the concentration of the agent. The viability of replicon cells was measured using the WST-8 cell counting kit according to the manufacturer's instructions (Dojindo, Kumamoto, Japan).

Western Blot Analysis of HCV NS3 and β -Actin. HCV replicon cells (1×10^6) were lysed with 100 μ l of lysis buffer (1% SDS, 0.5% Nonidet P-40, 150 mmol/l NaCl, 0.5 mmol/l EDTA, 1 mmol/l dithiothreitol, and 10 mmol/l Tris, pH 7.4). Five micrograms total protein was electrophoresed on a 10% SDS-polyacrylamide gel and subsequently transferred to a polyvinylidene difluoride membrane (Immobilon-P; Millipore, Billerica, MA). Nonstructural protein 3 (NS3) of HCV was detected using the rabbit anti-NS3 (R212) polyclonal antibody that was prepared in our laboratory. Beta actin was detected using anti- β -actin monoclonal antibody (Sigma, St. Louis, MO).

Immunosuppressive Activity of DEBIO-025 and CsA by Interleukin-2 Reporter Gene Assay In Vitro. We examined the immunosuppressive activities of DEBIO-025 and CsA using a nuclear factor of activated T cells-dependent IL-2 reporter gene assay (Fig. 1B).¹⁹ We used Jurkat T-cells stably expressing lac-Z controlled by the IL-2 promoter. The cells were grown in RPMI-1640 medium containing 10% fetal bovine serum, 2




Fig. 2. (A) Structure of HCV replicon genome. FLR3-1 and R6FLR-N were of similar construction. Encephalomyocarditis virus (EMCV), internal ribosomal entry site (IRES), untranslated region (UTR). (B, C) Effect of DEBIO-025 or cyclosporin A (CsA) on HCV replication, as monitored in triplicate by luciferase signal in the 2 HCV replicon systems. Data are expressed as percentages of the untreated control. Error bars indicate SD. (D, E) Effect of DEBIO-025 or CsA on viability of replicon-containing cells, as measured in triplicate by WST-8. Data are expressed as percentages of the untreated control. Error bars indicate SD. (F) Effect of DEBIO-025 or CsA on HCV NS3 protein or β -actin expression, shown by western blotting.

mmol/l glutamine, 50 μM 2-mercaptoethanol, and 100 U/ml hygromycin B. Jurkat T-cells were stimulated with phorbol-12-myristate-13-acetate (2.4 μM) and phytohemagglutinin (75 $\mu\text{g/ml}$) in the presence or absence of DEBIO-025 or CsA (10^{-9} to 2×10^{-5} mol/l). After incubation at 37°C for 20 hours, cells were harvested by lysis buffer (50 mmol/l Na_2HPO_4 , pH 9.0, 10 mmol/l KCl, 1 mmol/l MgSO_4 , and 1% Triton X-100), and then β -galactosidase activity in the lysate was measured using 4-methyl umbelliferyl- β -D-galactoside (0.5 mmol/l; Sigma).

HCV Infection into Chimeric Mice. We purchased chimeric mice from PhenixBio (Hiroshima, Japan). The chimeric mice were generated by transplanting human primary hepatocytes into severe combined immunodeficient (SCID) mice carrying the urokinase plasminogen activator transgene controlled by an albumin promoter.²⁰ The chimeric mice used in this study were improved from the original ones, as described by Tateno et al.,²¹ and had a high substitution rate of human hepatocytes. Six weeks after hepatocyte transplantation, we intravenously injected each mouse with patient serum containing 10^6 cop-

ies of HCV genotype 1a (HCG9) or 1b (HCR6).²² HCV inoculations, drug administration, blood collection, and killing were performed under ether anesthesia. Blood samples were taken from the orbital vein and sera were immediately isolated. The protocols for animal experiments were approved by the local ethics committee. The animals received humane care according to NIH guidelines. Patients gave written informed consent before sampling.

Measurement of Human Serum Albumin. Human serum albumin in the blood of chimeric mice was measured with a commercially available kit according to the manufacturer's instructions (Alb-II kit; Eiken Chemical, Tokyo, Japan).

Schedule for Administration of Agents into Chimeric Mice Infected with HCV Genotype 1b or 1a. Treatment was started 12 weeks after HCV inoculation and continued during 14 days (Fig. 3A and Fig. 4A). Each treatment group comprised 3 animals. Peg-IFN and DEBIO-025 in mice with HCV genotype 1a or 1b were administered as follows: either Peg-IFN (30 $\mu\text{g/kg}$) was injected subcutaneously twice weekly alone or DEBIO-




Fig. 3. (A) Schedule of experiments using chimeric mice infected with HCV genotype 1b. The mice were treated for 14 days with DEBIO-025 100 mg/kg/day orally, Pegylated-interferon α -2a (Peg-IFN) 30 μ g/kg subcutaneously twice weekly, or DEBIO-025 100 mg/kg/day orally combined with Peg-IFN 30 μ g/kg subcutaneously twice weekly. (B) Time course of serum HCV RNA levels in mice treated with DEBIO-025 (open squares), Peg-IFN (gray diamonds), or DEBIO-025 with Peg-IFN (closed triangles). Error bars indicate SD. (C) Human albumin concentrations in the sera of individual mice during the experimental period. (D) Body weight of individual mice during the experimental period.

025 (100 mg/kg) was given orally every day alone, or a combination of both drugs was given. CsA (100 mg/kg) was given orally every day combined with Peg-IFN (30 μ g/kg) subcutaneously twice weekly only to chimeric mice inoculated with genotype 1a.

Measurement of HCV Core Protein in Liver. Liver tissues were homogenized in lysis buffer (10 mM Tris pH 7.5, 1% SDS, 0.5% NP-40, and 150 mM NaCl) and centrifuged for 60 seconds at 16,000 g. HCV core protein was quantified using a commercially available kit (Ortho Clinical Diagnostics, Tokyo, Japan).²³

Quantification of HCV RNA by Real-Time Reverse Transcription PCR. HCV RNA in serum or liver tissue was extracted using the acid guanidinium-phenol-chloroform method. Quantification of HCV RNA was performed using real-time reverse transcription PCR based on TaqMan chemistry, as described.²⁴




Fig. 4. (A) Schedule of experiments using chimeric mice infected with HCV genotype 1a. The mice were treated for 14 days with DEBIO-025 100 mg/kg/day orally, Peg-IFN 30 μ g/kg subcutaneously twice weekly, DEBIO-025 100 mg/kg/day orally combined with Peg-IFN 30 μ g/kg subcutaneously twice weekly, or CsA 100 mg/kg/day orally combined with Peg-IFN 30 μ g/kg subcutaneously twice weekly. (B) Time course of serum HCV RNA levels in mice treated with DEBIO-025 (open squares), Peg-IFN (gray diamonds), or DEBIO-025 with Peg-IFN (closed triangles). Error bars indicate SD. (C) Body weight of individual mice during the first 7 days of the experimental period. All mice treated with CsA combined with Peg-IFN died within 4 days.

Immunohistochemistry. Liver tissues obtained from mice were embedded in OCT compound (Ted Pella, Redding, CA). The frozen tissues were cut into thin sections (6 μ m) and placed on glass slides. The sections were fixed in 10% buffered formalin and then treated with 0.1% Triton X-100. To detect HCV protein, the slides were incubated with rabbit anti-core protein IgG and then donkey anti-rabbit IgG polyclonal antibody [Fab fragment, labeled with horseradish peroxidase; Dako, Glostrup, Denmark]. The horseradish peroxidase label was amplified with FITC-conjugated tyramide according to the manufacturer's instructions (Molecular Probes, Eugene, OR). To detect human hepatocytes, liver sections were probed by anti-human hepatocyte monoclonal antibody (Dako), followed by anti-mouse IgG-Alexa 546 (Molecular Probes). Nuclei were stained by DAPI (Molecular Probes). Normal rabbit IgG was used as a control.

Results

Antiviral Activity of DEBIO-025 in HCV Subgenomic Replicon Cells. The anti-HCV effects of DEBIO-025 and CsA were initially confirmed using

HCV replicon cells. Both inhibited the replication of HCV replicon RNA in a concentration-dependent manner. The IC_{50} values of DEBIO-025 and CsA against replicon cell line of FLR3-1 were 0.06 $\mu\text{g}/\text{ml}$ and 0.31 $\mu\text{g}/\text{ml}$ respectively (Fig. 2B). The IC_{50} values of DEBIO-025 and CsA against replicon cell line of R6FLR-N were 0.07 $\mu\text{g}/\text{ml}$ and 0.27 $\mu\text{g}/\text{ml}$, respectively (Fig. 2C). The inhibitory effect of DEBIO-025 was approximately 5-fold greater than that of CsA. When cell viabilities were monitored using WST-8, DEBIO-025 differed from CsA by showing a reduction of cell viability only in R6FLR-N cells (CsA reduced cell viability in both types of replicon cells; Fig. 2D-E). In R6FLR-N cells, DEBIO-025 at 3.33 $\mu\text{g}/\text{ml}$ reduced cell viability by an average of 27.8%, whereas CsA at the same concentration reduced cell viability by an average of 57.2% (Fig. 2E). Western blotting of FLR3-1 cells showed that expression levels of NS3 protein, but not β -actin, were decreased by treatment with DEBIO-025 or CsA (Fig. 2F).

Immunosuppressive Activity of DEBIO-025. To examine the immunosuppressive activity of DEBIO-025, we used a nuclear factor of activated T cells-dependent IL-2 reporter gene assay. DEBIO-025 showed only a slight inhibitory effect on this system, with an activity that was 7,000-fold lower than that of CsA (data not shown). This indicates that the substitution of 2 amino acids in CsA to produce DEBIO-025 resulted in a greatly reduced immunosuppressive activity.

Human Albumin Levels in Mouse Serum After Transplantation of Human Hepatocytes. The concentration of human albumin in the serum of the chimeric mice was measured to provide an index of the substitution rate of mouse to human hepatocytes after transplantation.²¹ The concentration measured 20 days after transplantation of human hepatocytes was 3.5 to 6.0 mg/ml, indicating that human hepatocytes had settled into the chimeric mice. At 6 weeks after transplantation, we inoculated the mice with patient serum containing HCV genotypes 1a or 1b. We repeatedly measured the concentrations of human albumin after inoculation and found that they reached a plateau at approximately 6.5 mg/ml. Although the mice were infected with HCV, significant reductions of the human albumin concentrations were not observed (Fig. 5A-B).

Persistent Infection of HCV in Chimeric Mice. To determine whether the chimeric mice were persistently infected with HCV, we measured HCV RNA levels in serum weekly after the inoculation. HCV RNA disappeared at the first week and was then detected from 2 weeks after the inoculation. Four weeks after infection, HCV RNA levels reached 10^8 to 10^9 copies/ml in the genotype 1a group (Fig. 5C) and 10^6 to 10^7 copies/ml in




Fig. 5. Time course studies in 4 mice inoculated with human serum samples positive for HCV genotypes 1a or 1b. (A,B) Human albumin concentrations in mouse serum after transplantation of hepatocytes. (C,D) HCV RNA levels in mouse serum after inoculation.

the genotype 1b group (Fig. 5D). These results showed that our patient sera containing HCV had infected the chimeric mice. Furthermore, the increase of HCV levels in the serum was time dependent, indicating that HCV replicated and accumulated in the human hepatocytes of the chimeric mice.

Effect on HCV RNA Levels of DEBIO-025 and/or Peg-IFN in Mice Infected with HCV Genotype 1b. DEBIO-025 alone did not inhibit HCV replication, but Peg-IFN alone reduced serum HCV RNA levels approximately 10-fold from day 3 to day 14 (Fig. 3B). A 100-fold reduction was observed with the combined treatment (Fig. 3B). These results indicated an effect of DEBIO-025 that appeared to be synergistic with Peg-IFN against genotype 1b. The concentration of human serum albumin and the body weight of the mice did not change significantly during this period (Fig. 3C, D). After cessation of treatment, HCV RNA levels returned to 10^7 copies/ml.

Comparison of DEBIO-025 and CsA Effect in Chimeric Mice Infected with HCV Genotype 1a. The serum HCV RNA levels with the administration of DEBIO-025 or Peg-IFN alone seemed to be similar at day 7 and at day 14 as compared with those seen in mice infected with genotype 1b (Fig. 4B). The combined administration of DEBIO-025 with Peg-IFN resulted in a 600-fold reduction of HCV RNA levels at day 14 (Fig. 4B). The combined administration of CsA and Peg-IFN resulted in the death of all treated mice within 4 days. The

body weight of all CsA-treated mice was reduced by more than 20% during this period (Fig. 4C). The concentration of human serum albumin in the mice treated with CsA did not change significantly (data not shown). This toxicity was not observed with DEBIO-025 and Peg-IFN.

Quantification of Hepatic HCV RNA and Core Protein Levels and Immunohistochemistry at the End of Treatment in Chimeric Mice Infected with Genotype 1a. At the end of treatment, hepatic HCV RNA was quantified by real-time reverse transcription PCR, and core protein levels were quantified by enzyme-linked immunosorbent assay (Fig. 6A,B). DEBIO-025 monotherapy (1a-3 mouse) reduced HCV RNA by 3-fold compared with the nontreated mouse (1a-4 mouse). Peg-IFN reduced both HCV RNA and core protein levels by approximately 10-fold (1a-2 mouse). Combined treatment with DEBIO-025 and Peg-IFN resulted in an approximately 100-fold reduction in HCV RNA and HCV core protein levels (1a-1 mouse). Moreover, immunohistochemistry was performed. In 1a-4 mouse, HCV core protein was detected in human hepatocytes. In 1a-1 mouse, HCV core protein was not detected by immunohistochemistry; however, reduced HCV core protein was quantified by enzyme-linked immunosorbent assay, which is more sensitive than immunohistochemistry (Fig. 6C, D).

Discussion

Development of new anti-HCV drugs has been significantly impeded by the lack of a suitable cell culture model for the propagation of HCV in laboratories. This obstacle has been partially overcome by the development of the replicon system, which can be used for evaluating the *in vitro* anti-HCV effect of compounds. However, because adaptive mutation into the replicon genome and host permissiveness enable particularly efficient replication in cultured hepatoma cell lines,²⁵ evaluation of HCV drugs using replicon systems alone is considered insufficient. The only animal species readily infected with HCV has been the chimpanzee, which is labor-intensive and expen-




Fig. 6. Analysis of liver tissue from chimeric mice infected with HCV genotype 1a. (A) HCV RNA, and (B) HCV core protein, measured in triplicate in the livers of mice undergoing different treatment protocols. Severe combined immunodeficient (SCID) control: noninfected SCID mouse; 1a-1, mouse treated with DEBIO-025 combined with Peg-IFN; 1a-2, mouse treated with Peg-IFN; 1a-3, mouse treated with DEBIO-025; 1a-4, nontreated mouse infected with HCV. (C,D) Immunofluorescent labeling of human hepatocytes and HCV core protein, and fluorescent staining of nuclei. HCV core protein was labeled in human hepatocytes of nontreated chimeric mouse (C), but was not apparent in chimeric mouse treated with DEBIO-025 combined with Peg-IFN (D).

sive to use, and is associated with ethical problems. The chimeric mouse with human hepatocytes has recently been developed as a practical small animal model that can be infected with HCV.²⁰ This model is promising for the evaluation of new anti-HCV drugs because the mice are easy to handle, grow rapidly, and are well characterized genetically and immunologically. In this study, we used chimeric mice to bridge the gap between the replicon system and naive HCV replication in human liver, and to examine the anti-HCV effect of DEBIO-025, a novel cyclophilin inhibitor and non-immunosuppressive cyclosporin.

We found that HCV from our patient sera were able to infect the chimeric mice and persistently replicate over several weeks. HCG9 (1a) and HCR6 (1b) reached 10^8 to 10^9 copies/ml and 10^6 to 10^7 copies/ml, respectively, resulting in HCV RNA levels in serum that were higher than those previously reported.²⁰ This was probably because of a high substitution rate of human hepatocytes in the chimeric mice. When Mercer et al.²⁰ initially developed chimeric mice infected with HCV, they reported that human albumin concentrations in sera of the mice reached 2 mg/ml and that the substitution rate of liver from mouse to human was approximately 50%. In our study, the human albumin concentration in the chimeric mice reached 6.5 mg/ml, which would be consistent with a higher substitution rate of 80% to 90%.²¹ In addition, our findings also indicate that the plateau point of HCV RNA in serum depends on the type of inoculum, because the HCV RNA levels were different for HCG9 and HCR6. Taken together, the results suggest that our chimeric mice propagated large amounts of HCV in their livers.

Although DEBIO-025 strongly inhibited replication of the HCV replicon, it did not affect the replication of naive HCV *in vivo* when given as monotherapy. These results probably indicate differences between the replication of naive HCV *in vivo* and the replicon system. The sensitivity of HCV strains to CsA and non-immunosuppressive cyclosporins was variable, depending on their cyclophilin requirement for their replication.²⁶ Cyclophilin polymorphism and its role in HCV replication will be the focus of future study.

The HCV RNA levels are known to decline biphasically in most patients treated with IFN.²⁷ During the first phase, there is a rapid drop in viremia that reflects the direct inhibition of HCV replication. During the second phase, there is a slower decline in serum HCV RNA levels, which appears to reflect the elimination of infected cells by host immune responses. In chimeric mice, the second-phase decline is not obvious, because they lack T cells and B cells (being SCID). Thus, it appears that DEBIO-025

accelerates the decline in HCV RNA levels induced by Peg-IFN during the first phase. There is no evidence that DEBIO-025 enhances the interferon pathway. Also, recent *in vitro* findings show that cyclosporins do not modify the IFN- α signal transduction pathway as assessed by 2', 5'-oligoadenylate synthetase (2', 5'-OAS) levels.²⁸ It therefore seems likely that the apparent synergistic effect of DEBIO-025 seen in our *in vivo* model is not solely related to the antiviral effect mediated by IFN. The DEBIO-025 inhibition of cyclophilin may produce a proper anti-HCV effect by interacting with the RNA-dependent RNA polymerase.¹¹

CsA was originally used as an immunosuppressive agent, and we previously demonstrated in clinical trials that CsA has an anti-HCV effect.⁹ However, CsA is not devoid of adverse effects, such as hypertension, neurotoxicity, and nephrotoxicity, limiting its therapeutic usefulness against HCV.²⁹ The immunosuppressive action of CsA occurs by inhibition of calcineurin. Our findings showing that DEBIO-025 exhibits a 7,000-fold lower immunosuppressive activity than CsA suggest that it has less affinity to calcineurin and may lead to fewer adverse effects in patients.

In conclusion, our results indicate that naive HCV replication *in vivo* is inhibited by the combined administration of the cyclophilin inhibitor DEBIO-025 and Peg-IFN. These findings support further evaluation of DEBIO-025 as a promising drug for the treatment of chronic hepatitis C.

Acknowledgment: The authors thank Isao Maruyama and Hiroshi Yokomichi of PhenixBio Co., Ltd. for the maintenance of the chimeric mice.

References

1. Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, et al. Genetic organization and diversity of the hepatitis C virus. *Proc Natl Acad Sci U S A* 1991;88:2451-2455.
2. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. *N Engl J Med* 1999;341:556-562.
3. Bartenschlager R, Frese M, Pietschmann T. Novel insights into hepatitis C virus replication and persistence. *Adv Virus Res* 2004;63:71-180.
4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001;358:958-965.
5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncalves FL, Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002;347:975-982.
6. Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 2004;140:346-355.
7. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. *N Engl J Med* 1998;339:1485-1492.

8. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). *Lancet* 1998;352:1426-1432.
9. Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshida M. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. *J Gastroenterol* 2003;38:567-572.
10. Inoue K, Yoshida M. Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease. *Transplant Proc* 2005;37:1233-1234.
11. Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. *Mol Cell* 2005;19:111-122.
12. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral) in organ transplantation. *Drugs* 2001;61:1957-2016.
13. Kleinkauf H, Dittmann J, Lawen A. Cell-free biosynthesis of cyclosporin A and analogues. *Biomed Biochim Acta* 1991;50:S219-224.
14. Hansson MJ, Mattiasson G, Mansson R, Karlsson J, Keep MF, Waldmeier P, et al. The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria. *J Bioenerg Biomembr* 2004;36:407-413.
15. Chatterji U, Bobardt MD, Stanfield R, Prak RG, Pallansch LA, Ward PA, et al. Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in Owl monkey cells. *J Biol Chem* 2005;280:40293-40300.
16. Paeshuyse J, Kaul A, De Clercq E, Rosenwirth B, Dumont JM, Scalfaro P, et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. *HEPATOLOGY* 2006;43:761-770.
17. Sakamoto H, Okamoto K, Aoki M, Kato H, Katsume A, Ohta A, et al. Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. *Nat Chem Biol* 2005;1:333-337.
18. Watanabe T, Sudoh M, Miyagishi M, Akashi H, Arai M, Inoue K, et al. Intracellular-diced dsRNA has enhanced efficacy for silencing HCV RNA and overcomes variation in the viral genotype. *Gene Ther* 2006;13:883-892.
19. Burres NS, Premachandran U, Hoselton S, Cwik D, Hochlowski JE, Ye Q, et al. Simple aromatics identified with a NFAT-lacZ transcription assay for the detection of immunosuppressants. *J Antibiot (Tokyo)* 1995;48:380-386.
20. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, et al. Hepatitis C virus replication in mice with chimeric human livers. *Nat Med* 2001;7:927-933.
21. Tateno C, Yoshizane Y, Saito N, Karaoka M, Utoh R, Yamasaki C, et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. *Am J Pathol* 2004;165:901-912.
22. Tsukiyama-Kohara K, Tone S, Maruyama I, Inoue K, Katsume A, Nuriya H, et al. Activation of the CKI-CDK-Rb-E2F pathway in full genome hepatitis C virus-expressing cells. *J Biol Chem* 2004;279:14531-14541.
23. Aoyagi K, Ohue C, Iida K, Kimura T, Tanaka E, Kiyosawa K, et al. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. *J Clin Microbiol* 1999;37:1802-1808.
24. Takeuchi T, Katsume A, Tanaka T, Abe A, Inoue K, Tsukiyama-Kohara K, et al. Real-time detection system for quantification of hepatitis C virus genome. *Gastroenterology* 1999;116:636-642.
25. Bartenschlager R, Kaul A, Sparacio S. Replication of the hepatitis C virus in cell culture. *Antiviral Res* 2003;60:91-102.
26. Ishii N, Watashi K, Hishiki T, Goto K, Inoue D, Hijikata M, et al. Diverse effects of cyclosporine on hepatitis C virus strain replication. *J Virol* 2006;80:4510-4520.
27. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. *Science* 1998;282:103-107.
28. Goto K, Watashi K, Murata T, Hishiki T, Hijikata M, Shimotohno K. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. *Biochem Biophys Res Commun* 2006;343:879-884.
29. Erer B, Polchi P, Lucarelli G, Angelucci E, Baronciani D, Galimberti M, et al. CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors. *Bone Marrow Transplant* 1996;18:157-162.